Evidence map›Paper›PMID 40220171›Full record

ReviewApplied microbiology and biotechnology2025

Biosynthesis of ergothioneine: current state, achievements, and perspectives.

Shun Sato, Azusa Saika, Tatsuyuki Koshiyama, Yukihiro Higashiyama, Tokuma Fukuoka, Tomotake Morita

Abstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Observational
  2. Review
  3. Review
  4. Review
  5. Article
  6. EngineeringMicroorganisms · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shun SatoResearch Institute for Sustainable Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), Central 5, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan.
Azusa SaikaResearch Institute for Sustainable Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), Central 5, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan.
Tatsuyuki KoshiyamaNew Business Division, Kureha Corporation, 3-3-2 Nihonbashi-Hamacho, Chuo-ku, Tokyo, 103-8552, Japan.
Yukihiro HigashiyamaNew Business Division, Kureha Corporation, 3-3-2 Nihonbashi-Hamacho, Chuo-ku, Tokyo, 103-8552, Japan.
Tokuma FukuokaResearch Institute for Sustainable Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), Central 5, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan.
Tomotake MoritaResearch Institute for Sustainable Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), Central 5, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan. morita-tomotake@aist.go.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ergothioneine (EGT) is a derivative of the amino acid L-histidine that is well known for its strong antioxidant properties. Recent studies on the functional characterization of EGT in both in vivo and in vitro systems have demonstrated its potential applications in pharmaceuticals, food, and cosmetics. The growing demand for EGT in novel applications necessitates the development of safe and cost-effective mass production technologies. Consequently, microbial fermentation for EGT biosynthesis has attracted significant attention. This review focuses on the biosynthesis of EGT via microbial fermentation, explores its biosynthetic mechanisms, and summarizes the latest advancements for industrial EGT production using engineered microbial strains. KEY POINTS: • Ergothioneine (EGT) is an L-histidine derivative with strong antioxidant property. • Recent studies have revealed certain groups of microbes produce EGT naturally. • Superior EGT producers by genetic modification have been created.

Indexed as

BacteriaErgothioneineAntioxidantsBiosynthetic PathwaysFermentationIndustrial MicrobiologyMetabolic EngineeringAntioxidantsErgothioneineAntioxidantBasidiomycetesBiosynthesisErgothioneine

Identifiers

PMID40220171
PMCPMC11993508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.